This paper presents serial cardiac-catheterization data showing spontaneous functional closure of large symptomatic defects in 3 infants. One had an associated moderate-sized patent ductus arteriosus ...
Patients undergoing transcatheter atrial septal defect (ASD) closure did not have worsening migraines after completing a course of dual antiplatelet therapy, the CANOA investigators found. Overall, ...
Three months of clopidogrel is sufficient to curb new-onset migraine headaches after percutaneous atrial septal defect (ASD) closure, new data from the randomized CANOA trial show. There was no ...
NEW YORK - March 12, 2019-The Cardiovascular Research Foundation (CRF) is pleased to announce that the latest issue of Structural Heart: The Journal of the Heart Team features original research ...
Patients being treated with dual-antiplatelet therapy (DAPT) consisting of clopidogrel plus aspirin following atrial septal defect (ASD) closure can safely discontinue clopidogrel after 3 months ...
TCT 195: Percutaneous Patent Foramen Ovale Closure for Migraine with the Amplatzer PFO Occluder: A Pooled Analysis of Individual Participant Data from the Randomized Trials Receive the the latest news ...
The AI model was more efficient at detecting signatures of atrial septal defect (ASD) in electrocardiograms (ECG) than traditional methods. Investigators from Brigham and Women's Hospital, a founding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results